NASDAQ:INMD - IntegraMed America, Incorporation. Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IntegraMed America, Inc., is a United States-based company, which provides healthcare services. The Company manages clinical facilities which provide ART services to infertile couples. The ART program incorporates medical, psychological and financial counseling with ART (assisted reproductive technology) therapeutic procedures, such as in vitro fertilization (IVF), gamate intrafallopian transfer (GIFT) and microinsemination. It offers a suite of management support and infrastructure, which include: clinical and business information systems, sales and marketing, facilities and operations management, finance and accounting, human resources, legal and risk management and quality assurance.

Receive INMD News and Ratings via Email

Sign-up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:INMD
CUSIPN/A
Phone+1-914-2538000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

IntegraMed America, Incorporation. (NASDAQ:INMD) Frequently Asked Questions

What is IntegraMed America, Incorporation.'s stock symbol?

IntegraMed America, Incorporation. trades on the NASDAQ under the ticker symbol "INMD."

What is the consensus analysts' recommendation for IntegraMed America, Incorporation.?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntegraMed America, Incorporation. in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Has IntegraMed America, Incorporation. been receiving favorable news coverage?

Media coverage about INMD stock has trended positive on Friday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. IntegraMed America, Incorporation. earned a news impact score of 0.27 on Accern's scale. They also assigned media stories about the healthcare company an impact score of 47.02 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of IntegraMed America, Incorporation.?

Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact IntegraMed America, Incorporation.?

IntegraMed America, Incorporation.'s mailing address is 2 Manhattanville Rd, PURCHASE, NY 10577-2113, United States. The healthcare company can be reached via phone at +1-914-2538000.


MarketBeat Community Rating for IntegraMed America, Incorporation. (NASDAQ INMD)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  17 (Vote Underperform)
Total Votes:  45
MarketBeat's community ratings are surveys of what our community members think about IntegraMed America, Incorporation. and other stocks. Vote "Outperform" if you believe INMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.